Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]

Xiaofang Zhou, Hui Tao, Kai-hu ShiDrug 2022 · DOI · OpenAlex

Abstract

[This retracts the article DOI: 10.2147/DDDT.S146925.].
BibTeX
@inproceedings{zhou2022development,
  author = {Xiaofang Zhou and Hui Tao and Kai-hu Shi},
  title = {{Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]}},
  booktitle = {Drug},
  year = {2022},
  doi = {10.2147/dddt.s398024},
}

Loading related content...

Figure